Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Biopharmaceutical firm Xencor has entered into a technology licence agreement with Vir Biotechnology providing the latter with non-exclusive access to Xtend Fc technology.
Xencor’s Xtend technology will be used to extend the half-life of antibodies developed by Vir for the potential treatment of Covid-19 infection.
As part of agreement, Vir will exclusively carry out and fund the research, development, regulatory and commercial activities.
Financial details of the deal are yet to be divulged by either company. Xencor president and CEO Bassil Dahiyat said: “The Covid-19 crisis requires urgent and coordinated action by the biotechnology industry to develop